Capivasertib

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 223 publications

PITPβ Drives JAK2 V617F-Mediated Myeloproliferative Neoplasms by Promoting PtdIns(3,4)P ₂ -Dependent AKT Hyperactivation.

PITPβ Drives JAK2 V617F-Mediated Myeloproliferative Neoplasms by Promoting PtdIns(3,4)P ₂ -Dependent AKT Hyperactivation.

Journal: bioRxiv : the preprint server for biology

Published: April 10, 2026

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Clinicogenomic Landscape and Function of PIK3CA, AKT1, and PTEN Mutations in Breast Cancer.

Journal: JCO precision oncology

Published: April 09, 2026

PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib.

PTEN and PIK3CA Mutation Positive Breast Neuroendocrine Carcinoma Treated with Molecularly Targeted Therapy Including Capivasertib.

Journal: The Tohoku journal of experimental medicine

Published: March 11, 2026

Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning.

Neutrophil extracellular trap-related genes in PTCL: identification, prognosis and drug interaction prediction via bioinformatics-machine learning.

Journal: Hematology (Amsterdam, Netherlands)

Published: March 03, 2026

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

GARD: Genomic Data based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.

A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.

Journal: medRxiv : the preprint server for health sciences

Published: February 06, 2026

A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy

A Case of Hormone Receptor-Positive, HER2-Negative Metastatic Recurrent Breast Cancer Successfully Treated with Capivasertib and Fulvestrant in Late-Line Therapy

Journal: Gan to kagaku ryoho. Cancer & chemotherapy

Published: January 17, 2026

GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

GARD: Genomic Data-Based Drug Repurposing in Head and Neck Cancer with Large Language Model Validation.

Journal: Cancers

Published: January 16, 2026

Expanding The Scope of AKT Modulation Through Targeted Protein Degradation.

Expanding The Scope of AKT Modulation Through Targeted Protein Degradation.

Journal: Chimia

Published: December 30, 2025

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Journal: Science translational medicine

Published: December 17, 2025

Characteristic Glycemic Patterns During Capivasertib Treatment Identified by Continuous Glucose Monitoring: A Case Report.

Characteristic Glycemic Patterns During Capivasertib Treatment Identified by Continuous Glucose Monitoring: A Case Report.

Journal: Internal medicine (Tokyo, Japan)

Published: December 17, 2025

Continuous glucose monitoring reveals bimodal glycemic patterns during and outside Capivasertib administration.

Continuous glucose monitoring reveals bimodal glycemic patterns during and outside Capivasertib administration.

Journal: Journal of diabetes investigation

Published: December 10, 2025

Showing 1-12 of 223

Last Updated: 04/28/2026